Table of Contents
Table of Contents 2
List of Tables 4
List of Figures5
Introduction 6
Global Markets Direct Report Coverage 6
Dementia Associated With Alzheimer's Disease Overview 7
Therapeutics Development 8
Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview 8
Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis 9
Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies 10
Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 11
Dementia Associated With Alzheimer's Disease - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Dementia Associated With Alzheimer's Disease - Products under Development by Companies 15
Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes 16
Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development 17
Adamas Pharmaceuticals, Inc. 17
AgeneBio Inc. 18
Amarantus Bioscience Holdings, Inc. 19
Boehringer Ingelheim GmbH 20
Chase Pharmaceuticals Corporation 21
Eisai Co., Ltd. 22
H. Lundbeck A/S 23
MediPost Co., Ltd. 24
Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
(donepezil hydrochloride + solifenacin succinate) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BI-409306 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
E-2609 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
eltoprazine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Gln-1062 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
levetiracetam - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
LUAF-20513 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Neurostem - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
salicylamine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
TAK-070 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Dementia Associated With Alzheimer's Disease - Dormant Projects 59
Dementia Associated With Alzheimer's Disease - Discontinued Products 60
Dementia Associated With Alzheimer's Disease - Product Development Milestones 61
Featured News & Press Releases 61
Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation 61
Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer's Association International Conference 61
Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering & Investment Forum 63
Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website 63
Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression 64
Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference 66
Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer's Disease 67
Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia 67
Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer's Dementia 68
Jan 28, 2015: AgeneBio Receives Grant from Alzheimer's Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer's Dementia 69
May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories 70
May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016 8
Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 17
Dementia Associated With Alzheimer's Disease - Pipeline by AgeneBio Inc., H2 2016 18
Dementia Associated With Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 19
Dementia Associated With Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016 20
Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016 21
Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016 22
Dementia Associated With Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016 23
Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Assessment by Combination Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Dementia Associated With Alzheimer's Disease - Dormant Projects, H2 2016 59
Dementia Associated With Alzheimer's Disease - Discontinued Products, H2 2016 60

List of Figures
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016 8
Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Assessment by Monotherapy Products, H2 2016 25
Assessment by Combination Products, H2 2016 26
Number of Products by Top 10 Targets, H2 2016 27
Number of Products by Stage and Top 10 Targets, H2 2016 27
Number of Products by Mechanism of Actions, H2 2016 29
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Routes of Administration, H2 2016 31
Number of Products by Stage and Routes of Administration, H2 2016 31
Number of Products by Molecule Types, H2 2016 33
Number of Products by Stage and Molecule Types, H2 2016 33